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Objectives: To compare the treatments used to treat dentin hypersensitivity (DH), based on 
its efficacy and effect duration. 
 
Methods: Medline/PubMed, Cochrane Library, EMBASE, and ClinicalTrials were searched 
for articles published between January 1st, 2008 and November 14th, 2018, in English, 
Portuguese or Spanish, reporting clinical trials, completed and with results. This systematic 
review protocol was registered in PROSPERO, number CRD42019121986. 
 
Results: 74 randomized clinical trials were included in the systematic review, reporting 
patients from 16 to 65 years old, with a clinical diagnosis of DH, that evaluate the efficacy of 
a desensitizing product, compared to pre-treatment, used the evaporative method 
stimulation and the visual analogue scale. These studies evaluated 5366 patients and at 
least 9167 teeth. Seven follow-up periods were considered corresponding to an immediate, 
medium or long-time effect. 
 
66 studies were included in the quantitative synthesis. Glutaraldehyde with HEMA, glass 
ionomer cements and Laser present significant immediate (until 7 days) DH reduction. 
Medium term (until 1 month) reduction was observed in stannous fluoride, glutaraldehyde 
with HEMA, hydroxyapatite, glass ionomer cements and Laser groups. Finally, long term 
significant reduction was seen at potassium nitrate, arginine, glutaraldehyde with HEMA, 
hydroxyapatite, adhesive systems, glass ionomer cements, and LASER.  
 
Conclusions: All active ingredients show efficacy in DH reduction in different follow-up 
times. Only in-office treatments are effective in immediate DH reduction, maintaining its 
efficacy over time. For long time effects, at home treatments can also be used. More 
standardized evaluation protocols should be implemented to increase the robustly of the 
results. 
 
Keywords: Dentin Sensitivity (MeSH); Dentin Hypersensitivity; Dentin Hypersensitivity 
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MAIN TEXT 
BACKGROUND 
Dentin hypersensitivity (DH) can be defined as "short and acute pain from exposed dentin in 
response to thermal, evaporative, tactile, osmotic, or chemical stimuli, and the same pain 
cannot be related to another defect or dental pathology".1 
 
Despite being a widely studied theme, it remains a common problem in adults, with a 
prevalence ranging from 3% to 98%, for different included samples.2 More accurately, Zeola 
et al. in a systematic review and meta-analysis published in 2019, conclude that the 
prevalence is between 11% and 33%.3 At the same time, it is one of the dental pathologies 
most associated with pain and with lowest success in its treatment4, thus justifying a detailed 
analysis of the available treatment methods. 
 
Several theories have been proposed to explain the DH mechanism, with the hydrodynamic 
theory proposed by Brännström being the most accepted.5 According to this theory, external 
stimuli such as thermal, mechanical, evaporative and osmotic, lead to the movement of fluid 
within the dentinal tubules and this movement indirectly stimulates the pulp nerve ends, 
causing a painful sensation. Therefore, for DH to occur, there must be two situations: dentin 
must be exposed, either by the loss of enamel or by a gingival recession, and the dentinal 
tubules must be permeable both to the oral cavity and to the pulp.6 
 
DH treatment can be performed by several methods. In addition to the elimination of 
nociceptive stimuli, there are two main treatment strategies: modifying nervous response by 
preventing or reducing neuronal transmission and occluding the permeable dentinal 
tubules.7 As nervous modifiers, potassium salts such as potassium fluoride, potassium 
chloride, and the most commonly used, potassium nitrate stand out.8 Potassium alters the 
electrical potential of cells by depolarizing them. Because of this depolarization, there is a 
decrease in nervous excitability, and the cells are less responsive to stimuli.9,10 
 
Regarding tubular occlusion, numerous active principles have been described, both 
chemical: fluorides11, oxalates12, or arginine13,14 and physical: adhesives15 or laser 
therapies.16  
 
Fluorides indicated for DH treatment include sodium fluoride; silver diamide fluoride, tin 
fluoride, and amine fluoride. The application of fluorides creates a physical barrier since 
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The oxalates occlude the dentinal tubules by reacting with calcium ions from the oral cavity, 
causing a precipitation reaction that leads to the formation of insoluble calcium oxalate 
crystals.12  
 
Bioactive glasses, such as sodium, calcium phosphosilicate or calcium phosphate, promote 
the formation of apatite hydroxycarbonate, a mineral similar to hydroxyapatite, on the dentin 
surface, thus blocking the dentinal tubules.7 Glutaraldehyde will react with serum albumin in 
the dentinal fluid, leading to the formation of precipitates and subsequent reduction of the 
diameter and blockade of the dentin tubules.17 Arginine is an amino acid naturally found in 
saliva, and its combination with calcium carbonate reproduces the saliva’s ability to occlude 
and seal dentinal tubules, resulting in a barrier resistant to acids and temperature 
dissolution.13 Finally, strontium acts through the precipitation of particles on the dentin 
surface, thus preventing the movement of the dentinal fluid.18 
 
Iontophoresis can be associated with other agents and can be used as a desensitizing 
treatment, since it transfers the active agent into the dentinal tubules through electrical 
pressure.19–21 Physical agents such as resins, glass ionomer resins, and sealants, seal the 
dentinal tubules preventing the hydrodynamic stimulus to the pulp tissue.7  
 
Lasers act via different mechanisms according to intensity. High-intensity lasers such as Nd: 
YAG, Er: YAG, Er, Cr: YSGG and CO2, are used to obliterate the dentinal tubules.22 In 
contrast, low-intensity such as GaAlAs or He-Ne influence the reduction of pain symptoms, 
since they interfere with the Na+ K+ ion pump in the cell membrane, blocking the 
transmission of the pain stimulus.23 
 
However, and despite the diversity of available treatments, there is still no consensus as to 
efficacy, so there is no treatment described as ideal.24  
 
Thus, the objective of this systematic review is to compare the treatments used in dentin 
hypersensitivity, based on its efficacy and duration of action. 
 
The aim was to carry out a systematic review of the literature with a quantitative comparison 
of the results in order to answer the following problem, intervention, comparison, and 
outcome (PICO) question: "Which desensitizing agent is the most effective in reducing DH in 
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METHODS 
This systematic review was performed following the Preferred Reporting Items for 
Systematic Reviews (PRISMA) guidelines (http://www.prisma-statement.org) and the 
Cochrane Handbook of Systematic Reviews of Interventions (Version 5.1.0) 
 (http://handbook-5-1.cochrane.org/).25,26 
 
The protocol for this systematic review with meta-analysis was registered in PROSPERO 
with the number CRD42019121986. 
 
Search strategy 
The studies included in this systematic review were obtained from MEDLINE (accessed 
through PubMed), Cochrane Library, EMBASE and Clinical Trials databases. 
 
The search strategy was in Medline: (#1 (dentin sensitivity[MeSH] NOT bleaching) AND 
treatment), in Cochrane Library (#1 MeSH descriptor: [Dentin Desensitizing Agents] explode 
all trees; #2 MeSH descriptor: [Dentin Sensitivity] explode all trees]) and EMBASE (#1 
Entree descriptor: [Desensitizing Agent] explode all trees; #2 Entree descriptor: [Dentin 
Sensitivity] explode all trees]) and in Clinical Trials.gov: #1 (dentin hypersensitivity), using as 
filters publications between January 1st, 2008 and the November 14thof 2018,  in English, 
Portuguese or Spanish and reporting clinical trials, completed and with results. Two 
reviewers (T.N. and M.P.) independently evaluated and selected the studies that met the 
inclusion criteria. A third reviewer (CM.M) was consulted where there was uncertainty 
regarding eligibility, and a decision arrived at by consensus. 
 
Inclusion and exclusion criteria 
For this systematic review, only clinical studies which met the following inclusion criteria 
were selected: (1) randomized clinical trials (RCT); (2) clinical diagnosis of DH; (3) 
assessment of the efficacy of a desensitizing product, reporting DH reduction compared to 
pre-treatment; (4) adulthood (16 to 65); (5) evaluation of DH through the evaporative method 
and (6) measurement of results using visual analogue scale (VAS) in cm (0-10) or mm (0-
100). If the study has more than one follow-up all results were recorded. 
 
Exclusion criteria were: (1) in situ studies; (2) post-surgical cases; (3) periodontal or 
bleaching post-treatment cases; (4) hypnosis; (5) post restoration/preparation clinical cases; 
(6) non-randomized clinical studies; (7) case reports; (8) reviews; and (9) comparison 
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Data extraction 
The studies that fulfilled the inclusion criteria were processed for the extraction of data. The 
data was recorded as follows: first author and year of publication, study design (parallel or 
split-mouth), type of treatment, number of teeth, number of subjects, mean age of patients or 
age range, gender, mean difference of pain and percentage of DH reduction, both between 
baseline and follow-up. In studies reporting drop-outs the final number of patients included in 
the analysis was recorded. Mean difference of pain and percentage of DH reduction was 
recorded from studies or calculated when enough data was available. These data were 
extracted from each study and grouped by different follow-ups and treatments. The different 
follow-up times were set to 1 day, from 2 to 7 days, from 8 to 15 days, from 15 to 30 days, 
from 1 to 6 months and more than 6 months. The information for assessment of the risk of 
bias was also performed. The extraction of the information was done by two independent 
authors using a standard form. A consensus meeting was always held to confirm the 
agreement and to resolve any disagreement between the reviewers. 
 
Quality assessment 
The evaluation of the methodological quality of the included studies is essential for 
understanding the results. This quality of each RCT study was assessed using the bias risk 
assessment tool described in the Cochrane Handbook of Systematic Reviews of 
Interventions (Version 5.1.0).26 Briefly, six domains were evaluated: (1) random sequence 
generation to select the participants (selection bias); (2) allocation concealment (selection 
bias); (3) blinding intervention of participants and personnel (performance bias); (4) blinding 
of outcome assessment (detection bias); (5) incomplete outcome data (attrition bias); (6) 
selective reporting (reporting bias); and (7) other bias.  
 
Quantitative analysis of follow-up  
The quantitative analysis of the studies’ results was carried out whenever it was possible to 
extract numerical data. The articles that stated no quantitative data in the text or in tables 
were excluded due to the difficulty of reading these values graphically, which led to the 
exclusion of 8 articles.21,27–33 As in the systematic review, the results were grouped according 
to several follow-ups and treatments. In the analysis, the groups with less than two studies 
were excluded. In the extraction of data for statistical analysis the difference of the means or 
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Statistical analysis 
The IBM® SPSS® Statistics software, version 24.0 (IBM Corporation, Armonk, New York, 
USA) was used. Non-parametric tests were used after confirming the existence of at least 
one of the following two conditions: (1) non-normal distribution (assessed by Shapiro-Wilk 
test) or (2) number of cases per group of less than 10. 
For comparisons between two groups, the Mann-Whitney test was used. For comparisons of 
more than two groups, data were analyzed with the Kruskal-Wallis test. Multiple 





The PRISMA flow diagram of study selection is shown in Figure 1.  
 
All included studies are RCT and use VAS and the evaporative stimulation method as a 
method of assessing dentine hypersensitivity. The variation of sample size is very large 
among the studies, with samples varying from 7 to 250 teeth.  
 
Follow-up times were chosen according to the definition of therapeutic protocols, which may 
be immediate, medium-term and long-term. Most studies had more than one follow-up time, 
but most were immediate (up to 1 day) or medium-term (2 to 7 days, 8 to 15 days or 15 to 30 
days). The long-term evaluation, with follow-up of 3 to 6 months or more than 6 months, was 
performed in a small minority of studies.  
 
The treatments comprehended 24 active principles and a placebo group, as shown in Table 
2 in accordance with the codification read in this article. The code 25 – others includes LED 
therapy and biomimetic mineralization system (BIMIN). The number of studies analyzed for 
each treatment are reported in the table 2.  
 
Some were more represented in the literature, namely sodium fluoride, hydroxyapatite and 
laser. The placebo product used differs from study to study, and could be water, saline 
solution, glycerin, gel, sham treatments or no treatment. In the majority of studies there was 
a reduction of hypersensitivity in patients treated with the placebo group, with only 3 
reporting no difference or a slight increase at some follow-ups.4,34,35 Table 3 reports the 
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In the studies included in this systematic review a total of 5366 patients and at least 9167 
teeth were evaluated. Several studies reported only the number of subjects included but not 
the number of teeth, so it is possible that the sample is larger.  
 
At 1 day of follow-up, all treatments promote a reduction in DH, ranging from 0.8% (arginine) 
to 62% (Laser). Glass ionomer cements, resins, adhesives and Lasers presented the best 
results, although some variations were found in Laser results (table 3.1). At the time of 
second and third follow-ups, from 2 to 7 days and from 8 to 15 days, respectively, high 
values were reported in NaF groups, hydroxyapatite and laser groups, with an increase in 
DH reduction seen consistently in all the groups (Tables 3.2 and 3.3). From 15 to 30 days, 
glutaraldehyde together with resins, adhesives, and Lasers presented the best results, with 
hydroxyapatite, arginine, and NaF also presenting a significant reduction in DH-associated 
pain (Table 3.4). 
 
After 1 month and until 3 months, hydroxyapatite, resins, adhesives, glass ionomer cements, 
and lasers present several DH reductions above 80%, with all other treatments also 
presenting good results (Table 3.5).   
 
For long-term evaluation, 3 to 6 months and more than 6 months, evaluation can only be 
made for some of the treatments due to a lack of studies. Hydroxyapatite, adhesives, glass 
ionomer cements and Lasers maintain a reduction of DH above 80% (Tables 3.6 and 3.7). 
 
Some studies used associations of different treatments. As seen in table 3, these associated 
treatments usually result in an improvement of DH reduction, from about two times more. 
 
Methodological quality assessment of included studies 
The results of the quality assessment of RCTs of the systematic reviews can be seen in 
Appendix 1 and are schematically represented in Figure 2.  
 
Only one study presented flaws in the methodological description of random sequence 
generation, while about 5.4% presented insufficient information. The allocation concealment 
was not always explained properly (9.5%) or was not performed (5.4%). However, most 
studies present randomization and allocation concealment, and are considered as having 
low risk of selection bias. Blinding intervention of participants and personnel in clinical 
procedures was impossible in several studies (32.4%) or was not explained in the 
description of the clinical study (8.1%). This performance bias was more common since the 
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evaluation of the results was possible in most studies, with minimal risk of bias (74.3%). 
Attrition bias with incomplete outcome data, and reporting bias were present in 10.8% of 
RCT studies, which had to be excluded from the quantitative analysis. Other biases were of 
minimal risk in all scrutinized studies.  
 
Quantitative analysis of follow-up  
The different follow-ups were analyzed separately, and the results can be observed in Table 
4. 
For immediate follow-up, less than 1 day, the general comparison between treatments 
showed statistically significant differences (p < 0.0001). The treatments with glutaraldehyde 
(p < 0.001), glass ionomer cements (p < 0.05) and lasers (p < 0.01) demonstrated 
statistically significant differences compared to placebo.  
 
All the medium-term follow-ups showed significant differences between treatments. For the 
2-to-7 days group, there were statistically significant differences between the various groups 
with p = 0.007. Compared to placebo, there were some treatments that significantly reduce 
the hypersensitivity such as glutaraldehyde (p < 0.05) and lasers (p < 0.001). 
 
Similarly, for follow-up of 8 to 15 days, the general statistical differences between groups has 
a value of p = 0.001. However, a considerable number of studies were excluded with several 
treatments, namely: potassium chloride, amine fluoride, strontium acetate, iontophoresis, 
glutaraldehyde, strontium chloride, herbal, composite resins, dentin sealants, and potassium 
citrate. Nevertheless, the treatments analyzed showed a statistically significant reduction of 
hypersensitivity, namely stannous fluoride (p < 0.05), hydroxyapatite (p < 0.05), glass 
ionomer cements (p < 0.01) and lasers (p < 0.001).  
 
At 15 to 30 days there were statistically significant differences in the general comparison 
between groups with p = 0.001. A decrease in hypersensitivity can be observed consistently 
in some groups, such as glutaraldehyde (p < 0.001), hydroxyapatite (p < 0.01), glass 
ionomer cements (p < 0.01) and lasers (p < 0.001).  
 
In long-term follow-up times, it was only possible to analyze the treatments between 1 and 3 
months, because for the other times there were not enough samples to make the 
comparison. In the follow-up of 1 to 3 months there were statistically significant differences in 
the general analysis between groups (p < 0.0001). Many treatments showed significant 
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glutaraldehyde (p < 0.01), hydroxyapatite (p < 0.001), adhesive systems (p < 0.05), glass 
ionomer cements (p < 0.01) and lasers (p < 0.001).  
 
Treatments with glutaraldehyde, lasers and glass ionomer cements present statistically 
significant differences relative to placebo at different follow-up times. However, when the 
results in the same group are compared over time, they have no differences, being 
treatments that effectively reduce sensitivity from the 1st day with consistent results over 
time. Other treatments demonstrated reduced hypersensitivity relative to placebo with 
statistical significance in medium-term follow-up. From 8 to 15 days in treatment with 
hydroxyapatite, there was a statistically significant reduction of hypersensitivity relative to 
placebo and increasing significance over time. The treatments with potassium nitrate 
revealed statistically significant differences in the reduction of hypersensitivity only in the 
follow-up of 1 to 3 months. 
 
This analysis of the treatments’ effect over time can be observed in Appendix 2. Statistically 
significant differences at different follow-up times were observed in the treatments with 
potassium nitrate and hydroxyapatite, as shown in Figures 3 and 4 respectively. The 
treatment with potassium nitrate demonstrates a significant reduction of hypersensitivity at 
the beginning of the intermediate follow-up time, between 2 and 7 days (p < 0.01), with a 
less pronounced decrease in the other medium-term follow-up times, returning to the values 
initially obtained at 3 months (p < 0.001). 
 
Treatments with hydroxyapatite demonstrated a statistically significant efficacy in reducing 
hypersensitivity only from the 1st month (p < 0.05), which remains consistently up to 6 
months (p < 0.05). 
 
In laser treatments, there were no statistically significant differences over time in any follow-
up between high and low power.  
 
DISCUSSION 
Dentin hypersensitivity is a clinical condition that interferes greatly with patients' quality of 
life, namely with daily tasks such as talking, drinking, eating and toothbrushing.3 In a 
systematic review published by Douglas-de-Oliveira et al. in 2018, it was concluded that the 
treatments for dentin hypersensitivity result in a decrease in the physical symptoms of pain 
and an increase in the psychological dimension of comfort and consequently an 
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performing clinical research in this field.97 However, despite the great number of articles 
published, the methodologies used vary greatly among them. DH evaluation can be done 
using various stimuli, such as thermal, tactile or evaporative. For the present systematic 
review, only studies that performed DH stimulation through the evaporative method were 
considered. The choice was because it involves the stimulation of a greater area of dentin, it 
was the type of stimulus most commonly reported, since it is the most reproducible of the 
three, and it is also the most physiologically controllable.24,75,98 Regarding the methods of 
evaluating DH, the VAS; Visual Rate Scale (VRS) and Schiff Cold Air Sensitivity Scale 
(SCASS), can be used. VAS consists of a straight line of 10 cm where the extremities are 
defined as "No pain" and "Severe pain". It is usually used from 0-10 cm or 0-100 mm.99 The 
VAS evaluation was used in the present review since it is considered as an objective method 
to determine dentin pain1, it is the most widely used method described in the literature, and 
allows us to obtain quantitative results. Studies which used other measurement instruments 
were not included in this review. Also, the fact that pain is subjective to each individual and 
each patient responds differently, as well as the fact that sometimes they do not understand 
the scales used, may have some impact on the results of the studies.  
 
Interestingly, some studies reported significant DH reduction in groups absent from active 
principle30,75,87,91,92,100, indicating the possible contribution of the placebo effect or even the 
Hawthorne effect on the action of desensitizers.101 In the case of the placebo effect, the 
participants would present a physiological response after administration of an inert agent, 
such as saline solution. Regarding Hawthorne's effect, unpredictable results could be due to 
behavioral and emotional changes in the participants because they knew that they were 
taking part in a study or that they would be subject to observation by examiners.102 The 
influence of these effects is difficult to calculate and should be considered. The existence of 
these placebo control groups may give additional information about the efficacy of the 
agents tested, allowing a better interpretation of the results; however, the use of negative 
controls in DH trials is controversial, since some authors support that, for ethical reasons, 
treatments without an active ingredient should not be performed. In some of the studies, 
positive control groups with fluoride dentifrices were used.29,35,88,90,92,94,46,51,62–64,68,74,81 These 
pastes should not be used as a negative control, as stated by some authors, as they may 
have different fluorides or other agents, and it is not clear which fluoride concentration is 
effective in the treatment of DH.1 As for the positive controls, since there is no gold standard 
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Despite a Cochrane meta-analysis103 reporting that there is no significant improvement with 
the use of potassium nitrate as a desensitizing agent, the present review shows that 
potassium nitrate is effective in the treatment of DH. All included studies of the different 
potassium salts reported a statistically significant treatment effect between the start of 
treatment and the last follow-up period, including in cases of association with other possible 
treatment agents. These differences between the present review and that of Poulsen et al. 
2006 may be due to the studies included since we only included studies from 2008 on, the 
percentage of potassium in the agents used or methods of determination of DH reduction.  
 
As mentioned, within the tubule occluders there are several options: bioactive glasses, 
fluorides, oxalates, iontophoresis, arginine, strontium, and glutaraldehyde. According to this 
systematic review, desensitizing agents that use sodium phosphosilicate calcium, calcium 
phosphate or nano-hydroxyapatite contribute to the improvement of the symptoms of DH. As 
regards sodium and calcium phosphosilicate, the results of this study corroborate the results 
of the review by Zhu et al.104, since they present a statistically significant treatment effect in 
all included studies. 
 
In the present review, several fluorides were found for DH treatment, namely sodium 
fluoride, silver diamide fluoride, tin fluoride, and amine fluoride. Because it is commonly used 
in clinical practice, as previously stated, sodium fluoride was mostly used as a negative 
and/or positive control; however, all studies reported a decrease of DH with its use. The 
efficacy of DH reduction by fluoride action is supported by its mechanism of action, with 
formation of precipitated and dentinal tubule occlusion.105 Also, in the remaining fluorides, all 
studies revealed the significance of treatment effect values.  
 
Desensitizing agents that use oxalates improve the symptomatology of DH, revealing a 
statistically significant treatment effect in all studies included in this systematic review. These 
results do not meet the meta-analysis of Cunha-Cruz et al., which states that there is no 
benefit in the use of oxalates for the treatment of DH106, but again the inclusion of different 
studies and study methodology can support this difference. 
 
Arginine-based dentifrices have also been used as desensitizers with positive results in 
more than one systematic review.107,108 The results of this review show that there are 
significant improvements in DH when treated with arginine-based products, but only with 
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Strontium in the form of strontium acetate or strontium chloride may be an effective method 
of DH treatment, but the statistical analysis was not performed due to an insufficient number 
of studies.54,59,68,79,85 
 
In vitro studies have shown that the Spinacia oleracia agent is effective in the occlusion of 
dentinal tubules through the formation of calcium oxalate crystals. In this review, 3 studies 
were included that refer to a statistical improvement in DH with the use of herbal dentifrices, 
two of which refer to the agent Spinacia oleracea.79,92,93 However, the presence of potassium 
nitrate in the composition of the described dentifrices does not allow a correct understanding 
of the true nature of the desensitizing effect of Spinacia oleracia in the treatment of DH, 
since this effect may be due to the nitrate in the composition of the product.  
 
A study by Azarpazhooh et al., which uses ozone to treat DH, shows a statistically significant 
improvement in DH.87 However, the true effect of ozone can be difficult to determine, since 
these results may have been achieved through a vacuum effect that will lead to the 
dissection and evaporation of the more superficial dentinal fluid. This dissection results in the 
deposition of salts in the dentinal tubules that lead to its filling, thus causing a relief in the 
symptomatology.87 
 
Regarding physical agents, the use of lasers has been increasing in the dentistry field and 
DH treatment is no exception, being described first by Matsumoto et al.109 There are several 
systematic reviews and meta-analyses that report that lasers are effective in the treatment of 
DH22,110,111, which is in agreement with the results we obtained. 
 
One of the major limitations of the studies included in this review is that many have a short 
follow-up. In clinical practice, when patients seek treatment for DH, they seek long-term 
results, so follow-up times should last until the agent used has the maximum effect to reduce 
the placebo effect mentioned above. Another problem is the small number of studies in 
some of the categories presented, which means that the sample included in some groups is 
reduced, limiting the conclusions obtained. Although parameters such as DH assessment 
and stimulus type were chosen to decrease heterogeneity, this is also a major limitation 
since there are different study designs (parallel or split-mouth) and different follow-ups in the 
studies selected for this review. This heterogeneity is most noticeable in studies involving 
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Even though we chose the evaporative method analyzed with the VAS that guaranteed an 
objective and quantitative analysis, we thought that some recommendations for future 
studies would be important:  
1. Age stratification of the sample should be performed since some studies reported 
included individuals ranging from 18 to 65/70 years old. Since the incidence of HD 
varies greatly with age, besides other factors, more homogenous age samples 
should be evaluated. 
2. The spilt-mouth design should be chosen wherever possible since it allows to 
evaluate the response to HD treatment in the same individual. In situations were 
split-mouth design cannot be performed, such as dentifrices evaluation, a control 
group should always be included. 
3. Control groups with placebo should be performed in all studies since the published 
results show a decrease in HD attributed to a placebo effect. The chosen placebo 
should be adapted to the evaluated treatment. In a situation as laser or 
iontophoresis, the placebo should be performed with the treatment simulation. In 
chemical agents, the placebo should be chosen accordingly the pharmaceutical 
formulation: glycerin gel or saline solution should be used as a placebo where gel 
formulations or liquid formulations are tested, respectively. 
4. HD evaluation should be performed with the evaporative method, since it gives the 
most accurate results, for the reasons stated above.  The distance between the air 
spray and dental structure, the air spray pressure, and the test duration should be 
standardized. After isolation of the adjacent teeth, the air syringe should be placed 2-
3 mm from the tooth surface, at a perpendicular position of 90º, and a continuous air 
blast of 45 to 60 psi should be applied for 2 to 3 seconds. The air temperature should 
be around 20º C (19-22ºC). 
5. Combined evaluation with 2 methods can be used, as the evaporative and tactile 
method, since it gives a more accurate result. The results of the methods should be 
reported separately, and a combined score should also be included.  
6. VAS should be used to evaluate the HD reduction since it gives a quantitative result. 
Combined evaluation with other scales can be performed, but again, results should 
be reported separately and in a combined score. 
7. Studies should include follow-ups that allow evaluating the immediate, medium and 
long-term effect of the treatment in the same sample. HD evaluation should be 
performed at 1 day, 1 week, 1 month, 3 months and 6 months. 
We believe that these factors may influence the test results and to obtain further clinical 
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CONCLUSION 
The results of the present review demonstrate positive levels of efficacy in all treatment 
options for DH reduction, irrespective of the mechanism of action.  
 
With the accomplishment of this systematic review and quantitative analysis of follow-up, the 
most effective agent in the treatment of DH was determined. In office treatments both 
chemical as glutaraldehyde with HEMA, or physical as glass ionomer cements or Laser are 
effective in immediate reduction of DH associated pain, maintaining its efficacy over time. 
For long time effects, at home treatments with chemical agents, such as potassium nitrate, 
arginine or hydroxyapatite can also be used to treat DH with significant results. 
 
In the treatment of dentin hypersensitivity, in addition to the appropriate choice of 
desensitizing agent, it is important to evaluate the predisposing factors 112. This evaluation is 
fundamental to assess the risk of exposure of dentin tissue by enamel removal, as occurs in 
patients with very acidic diets, for example. A therapy with a desensitizing agent, as a 
minimally invasive, cost-effective, and safe treatment is also reversible, and therefore the 
result is dependent on the removal of the causative agent.  
 
In order to understand the best option among the different groups, a greater homogeneity of 
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Tables legends 
Table 1 – Schematic representation of PICO question 
 
Table 2 – Codification and number of studies included for each treatment 
 
Table 3 - 3.1 - Summary of the included studies on the systematic review up to 1 day; 3.2 - 
from 2 to 7 days; 3.3 - from 8 to 15 days; 3.4- from 15 to 30 days; 3.5 - from 1 to 3 months; 
3.6 - from 3 to 6 months and 3.7 - more than 6 months. 
 
Table 4 – P values referent to the statistical comparison between DH reduction of each 
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Table 1 – Schematic representation of PICO question 
Population / Problem Adult patients with DH 
Intervention Desensitizing Treatments 
Comparison Placebo or No treatment 
Outcome Pain Reduction  
 
 
Table 2 – Codification and number of studies included for each treatment 
Code Treatment Number of studies 
1 Placebo 24 
2 Potassium nitrate 17 
3 Potassium chloride 1 
4 Potassium fluoride 1 
5 Sodium fluoride (NaF) 33 
6 Stannous fluoride 6 
7 Amine fluoride 1 
8 Strontium acetate 4 
9 Oxalates 9 
10 Iontophoresis 2 
11 Arginine 12 
12 Glutaraldehyde + HEMA 18 
13 Chlorhexidine 1 
14 Strontium Chloride 3 
15 Hydroxyapatite 20 
16 Herbal 3 
17 Ozone 1 
18 Composite resins 3 
19 Adhesives systems 7 
20 Glass ionomer cements  3 
21 Dentin sealants 3 
22 Laser 21 
23 Potassium Citrate 1 
24 HEMA 1 
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Percentage of DH 
reduction between 
baseline and final  
follow-up 





1 Distilled Water (Placebo) 
208 52 
33.42 
26 M /26 W 
-2.23 3.6 
2 3% Potassium Nitrate (Ultra EZ) -10.77 17 
5 Sodium Fluoride (Duraphat) -9.15 16 
12 Glutaraldehyde (Gluma Desensitizer) -8.23 15.1 





1 NaF Placebo 64 
48 
41 
22 M / 26W 
-3.8 5.9 
1 LASER Placebo 64 -2.3 3.7 
5 NaF Varnish 58 -54 79.9 
22 GaAlAs Diode LASER 500mW 810 nm 58 -46.7 74.1 










5 2% Sodium Fluoride Solution 64 NR 41 
10 Iontophoresis 2% Sodium Fluoride Solution (Desensitron II) 65 NR 89 
12 5% Gluteraldehyde (GLUMA®) 65 NR 80 





1 Water (placebo) 
150 50 
32.4 
32 M / 18 W 
-33.8 51.7 
9 Oxalic Acid (BisBlock) -26 41.8 
12 Glutaraldehyde (Gluma Desensitizer PowerGel) -50 77.4 





1 Placebo 22 
21 
37 
5 M / 16 W 
-1.09 2.9 




22 Low Level Laser 685 nm 25 mW (LLL) 41 -23.41 48.8 
11 + 22 LLL followed by DP 29 -25.28 46 
11 + 22 DP followed by LLL 32 -20.9 34 





1 Distilled Water (Placebo) 16 
16 
34.31 
8 M/ 8 W 
-2.25 3,7 
1 Placebo LASER 16 -0.75 1,1 
12 Glutaraldehyde (Gluma Desensitizer) 16 -26.25 40.4 
22 GaAlAs Diode LASER Low Level 655 nm 25mW 16 -29.5 43.5 





1 Control (no treatment) 7 
28 NR 
-19 NC 
22 Er:YAG LASER  (0,64W/5.9 J/cm2) 7 -29.4 NC 
22 Er,Cr:YSGG LASER  (0.25 W/4.4 J/cm2) 7 -15.7 NC 
22 Er,Cr:YSGG LASER (0.50 W/ 8.9 J/cm2) 7 -18.7 NC 





1 Control (no treatment) 
174 51 
44 
22 M / 29 W 
-3 4,3 
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22 GaAlAs Diode LASER 810 nm  -54 76.1 





1 LASER Er, Cr:YSGG without emission (Placebo) 
146 42 
33.8 
18 M / 24 W 
-7.6 11 
22 LASER Er, Cr:YSGG 0,25W -55.5 79.1 





1 Not Irradiated (control) 
96 24 
34 
11 M / 13 W 
-0.8 1 
22 Er:YAG LASER 2,940-nm -7.9 9.5 
22 Nd:YAG LASER 1064 nm 1W -33.4 39.9 
22 GaAlAs Diode LASER 808 nm 100mW -5.4 6.5 
 





2 Potassium Nitrate (Isodan) 10 
10 33.42 
2 M / 8 W 
-8 26.7 
5 5% NaF Varnish (Shellac F) 20 -10 25.6 
5 NaF Varnish (Duraphat) 10 -15 46.9 





2 Potassium nitrate-based toothpaste (Villevie prophylactic 
pasteb + Sensodyne Pronamelc, potassium nitrate and 
sodium fluoride- toothpaste) 
NR 50 34.18 
13 M / 37 W 
-6 7.6 
11 
8% arginine and calcium carbonate (Colgate Sensitive Pro-
Relief Toothpaste) + 8% arginine, calcium carbonate and 
1,450 ppm fluoride (Colgate Sensitive Pro-Relief Desensitizing 
Paste with Pro-Arginine Technology) 
-20 25.3 





3 3.75% Potassium Chloride Dentifrice (Sensodyne F) 26 
13 31.2 
6 M / 7 W 
-5.4 6.7 
3 + 22 Erbium and Diode LASER 100 mW 808 nm + 3.75% Potassium 
Chloride Dentifrice (Sensodyne F) 
26 -8.5 10.5 





5 5% NaF Varnish (Duraphat) 
76 19 NR 
6 M / 13 W 
-26.95 47.1 
9 3% Potassium Oxalate Gel (Oxa-Gel) -15.32 26.7 
19 Self-Etch Adhesive (Clearfil SE Bond) -1.42 3 
22 High Intensity Diode LASER 810–830 nm 0.5–4.5 W -9.95 18 





1 Distilled Water (Placebo) 127 
68 33.8 
36 M /32 W 
3 -5.7 
5 5% NaF Varnish (Copal F) 127 -39 69.6 
11 8% Arginine Calcium Carbonate Dentifrice (Pro-Relief) 127 -32 55.2 
12 5% Glutaraldehyde (Gluma Desensitizer) 127 -39 67.2 





1 2% Sodium Fluoride Gel (Flugel) 27 
23 20-65 
3 M / 20 W 
-25 NC 
22 GaAlAs LASER, 40 mW 29 -52 NC 
22 Nd:YAG LASER, 1 W 33 -49.4 NC 









19 Admira Protect 28 -25 100 
19 PRG-Barrier Coat 28 -30 100 





5 4 a 6 % NaF Varnish (Flor-Opal® Varnish) 31 
46 NR 
19 M / 27 W 
-20 50 
18 Flow Resin (Vertice Flow) 28 -30 75 
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21 Sealant (Universal Dentine Sealant) 27 -30 60 





5 2% NaF solution 65 
24 38 
8 M / 16 W 
-33 51.6 
12 Glutaraldehyde (Gluma desensitizer) 67 -50 75.8 
22 Diode LASER  320 nm 69 -52 72.2 
5 + 22 NaF + Diode LASER 61 -57 82.6 




Parallel 5 NaF Varnish (Bifluorid 12) NR 20 37 
8 M / 12 W 
-20.3 28.6 
22 Nd:YAG LASER 1.064 2W NR -46.8 66.7 





5 6% NaF Varnish (Biflouride 12) 
225 40 NR 
-10.3 30.6 
11 8% Arginine Calcium Carbonate Dentifrice (DP) (Colgate 
Sensitive Pro-Relief) 
-10.3 37.5 
19 Adm ra Protect -17.4 50.3 




Parallel 5 NaF Dentifrice (Crest® Decay Prevention Toothpaste) NR 19 43.5 
1 M / 18 W 
-12.2 35.3 
8 8% strontium acetate Dentifrice (Sensodyne® Rapid Relief) NR -1.1 2.7 
 








35 M / 76 W 
-2.26 2.9 
6 0,454% stannous fluoride (Crest® Pro-Health™ Sensitive 
Shield) 
NR -11.65 15.1 




Parallel 5 1450 NaF Dentifrice  NR 79 41.6 
12 M / 67 W 
-9.3 20 
6 8% Strontium Acetate Dentifrice (Sensodyne Rapid Relief) NR -18.1 45 





Parallel 5 0,76% sodium monofluorophosphate (Colgate Cavity 
Protection) 
NR 118 36.3 
44 M / 74 W 
-7.97 13.2 
6 0.454% w/w stannous fluoride dentifrice (Crest Sensitivity - 
Treatment and Protection) 
NR -11.29 18.8 





Parallel 5 0,76% sodium monofluorophosphate (Colgate Cavity 
Protection) 
NR 120 29.5 
45 M / 75 W 
-9.12 15.2 
6 0.454% stannous fluoride dentifrice NR -4.05 7.6 








6 M / 75 W 
-16.2 23.2 
11 8% arginine, calcium carbonate, and 1450 ppm fluoride 
(Colgate Pro-Relief) 
NR -0.6 0.8 




Parallel 8 8% Strontium Acetate Dentifrice (Sensodyne Rapid Relief) NR 
80 NR 
25 M / 55 W 
-9.12 NC 
11 8% Arginine Calcium Carbonate Dentifrice (Colgate Sensitive 
Pro-Relief) 
NR -8.7 NC 




Split-mouth 9 Oxalic Acid Gel 2% (Pain-Free) 44 
11 47 
4 M /7 W 
-14.3 42.8 
9 Oxalic Acid Gel (BisBlock) 43 -27.4 51.0 
18 Resine (Seal and Protect) 44 -32.8 63.8 




Split-mouth 9 Potassium Binoxalate Gel (D/Sens Crystal) 40 20 25 - 55 
10 M / 10 W 
-62 79.5 
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Parallel 12 Glutaraldehyde (Gluma Desensitizer) 18 
20 18 - 35 
8 M / 12 W 
-46 63 
19 Universal Adhesive (Single Bond Universal) 18 -47 63.5 
12 + 19 Glutaraldehyde with Adhesive (Gluma Comfort Bond + Gluma 
Desensitizer) 
18 -43 58.9 




Split-mouth 12 Glutaraldehyde (Gluma Desensitizer) 13 
32 22 - 53 
NR 
-35 74.5 
22 LASER Low Power Low Dose (LPLD) 810 nm 30 mW 13 -12 51.1 
22 LASER Low Power High Dose (LPHD) 810nm 100 mW 13 -13.5 36.5 
22 Nd:YAG LASER 1064 nm 1 W 13 -26 56.5 
22 + 22 LPLD + Nd:YAG LASER 1064 nm 13 -19.5 45.9 
22 + 22 LPHD + Nd:YAG LASER 1064 nm 13 -24.5 40.2 
12 + 22 LPLD + Glutaraldehyde (Gluma Desensitizer) 13 -40 65.6 
12 + 22 LPHD + Glutaraldehyde (Gluma Desensitizer) 13 -15 23.1 
22 + 12 Nd:YAG LASER + Glutaraldehyde (Gluma Desensitizer) 13 -42 71.2 




Split-mouth 12 Glutaraldehyde (Gluma Desensitizer) 11 
27 22 - 53 
NR 
-20.21 43 
22 Low Power Laser Low Dose 30mW 810 nm (LPLLD) 11 -10.34 44 
22 Low Level Laser High Dose 100mW 810 nm (LPLHD) 11 -10.73 29 
22 + 12 LPLLD + Glutaraldehyde (Gluma Desensitizer) 11 -29.28 48 
22 + 12 LPLHD + Glutaraldehyde (Gluma Desensitizer) 11 -20.8 32 




Split-mouth 12 5% Glutaraldehyde (Gluma Desensitizer) NR 250 20 - 55 
140 M / 160 
W 
-28.9 41.9 
13 1% Chlorhexidine (Cervitec) NR -41.7 58.7 





19 Self-Etch Adhesive (Clearfil SE Protect) 
179 30 32,5 
NR 
-45 90 
19 Total Etch Adhesive with Glutaraldehyde (Gluma 2 Bond) -46 83.6 
20 Resin-Modified GIC (ClinproTM XT) -52 88.1 




Split-mouth 20 Resin-Modified GIC (ClinproTM XT) 70 20 42.7 
3 M / 17 W 
-37 72.5 
20 Convencional GIC (Vidrion R) 82 -42 70 





1 Warm water (placebo) 
119 31 46.9 
13 M / 18 W 
NS VNR 
12 Gulma Dentin Desensitizer SS VNR 
20 Clinpro XT Varnish  SS VNR 




Split-mouth 1 Distilled Water (Placebo) NR 35 33.3 
10 M / 25 W 
SS VNR 
15 Teethmate AP  NR SS VNR 





12 Glutaraldehyde (Gluma Desensitizer Power Gel) NR 
49 NR 
16 M / 34 W 
SS VNR 
15 Teethmate Desensitizer  NR SS VNR 
21 NanoSeal NR SS VNR 
21 MS Coat One F NR SS VNR 









22 Nd:YAG Laser  1.5W, 10Hz, 100mJ 11 SS VNR 
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M: men; W: women; NR: not reported; NC: not calculated; CNR: composition not reported; SS: statistically significant; NS: not statistically significant; VNR: 
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Percentage of DH 
reduction between 
baseline and final  
follow-up 





1 Distilled Water (Placebo) 
208 52 
17-51 
26 M / 26 W 
-1.62 2.6 
2 3% Potassium Nitrate (Ultra EZ) -57.38 90.4 
5 Sodium Fluoride (Duraphat) -51.53 90.2 
12 Glutaraldehyde (Gluma Desensitizer) -48.07 88.4 





1 NaF Placebo 64 
48 
41 
22 M / 26W 
-3.2 5.0 
1 LASER Placebo 64 -1.5 2.4 
5 NaF Varnish 58 -54.8 81.1 
22 GaAlAs Diode LASER 500mW 810 nm 58 -47.9 76 





1 Water (placebo) 
150 50 
32.4 
32 M / 18 W 
-33.8 51.7 
9 Oxalic Acid (BisBlock) -21.6 34.7 
12 Glutaraldehyde (Gluma Desensitizer PowerGel) -48.1 74.5 





1 Distilled Water (Placebo) 16 
16 
34.31 
8 M / 8 W 
-2.25 3,7 
1 Placebo LASER 16 0 0 
12 Glutaraldehyde (Gluma Desensitizer) 16 -55.25 85 
22 GaAlAs Diode LASER Low Level 655 nm 25mW 16 -59 87.1 





1 Control (no treatment) 7 
28 NR 
-12.3 NC 
22 Er:YAG LASER  (0,64W/5.9 J/cm2) 7 -27 NC 
22 Er,Cr:YSGG LASER  (0.25 W/4.4 J/cm2) 7 -3.4 NC 
22 Er,Cr:YSGG LASER (0.50 W/ 8.9 J/cm2) 7 -19.3 NC 





1 Control (no treatment) 
174 51 
44 
22 M / 29 W 
-4 5.8 
22 Er,Cr:YSGG LASER  2780 nm 0,25W -60 83.3 
22 GaAlAs Diode LASER 810 nm  -55 77.5 





1 LASER Er, Cr:YSGG without emission (Placebo) 
146 42 
33.8 
18 M / 24 W 
-7.7 11.2 
22 LASER Er, Cr:YSGG 0,25W -54.3 77.4 





1 Distilled Water (Placebo) 127 
68 
33.8 
36 M /32 W 
2 -3.8 
5 5% NaF Varnish (Copal F) 127 -40 71.4 
11 8% Arginine Calcium Carbonate Dentifrice (Pro-Relief) 127 -32 55.2 
12 5% Glutaraldehyde (Gluma Desensitizer) 127 -42 72.4 





5 2% Sodium Fluoride Gel (Flugel) 27 
23 
20-65 
3 M / 20W 
-30 NC 
22 GaAlAs LASER, 40 mW 29 -65.3 NC 
22 Nd:YAG LASER, 1 W 33 -65.9 NC 
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 19 Admira Protect 28 NR -25 100 
19 PRG-Barrier Coat 28 
 
-27 90 





5 4 a 6 % NaF Varnish (Flor-Opal® Varnish) 31 
46 
NR 
19 M / 27 W 
-20 50 
18 Flow Resin (Vertice Flow) 28 -30 75 
19 Adhesive (Clearfil Protect Bond) 30 -20 50 
21 Sealant (Universal Dentine Sealant) 27 -30 60 





5 NaF Varnish (Bifluorid 12) NR 
20 
37 
8 M / 12 W 
-30.1 42.5 
22 Nd:YAG LASER 1.064 2W NR -48.1 68.5 





5 6% NaF Varnish (Biflouride 12) 
225 40 NR 
-9.3 27.6 
11 
8% Arginine Calcium Carbonate Dentifrice (Colgate Sensitive 
Pro-Relief) 
-10.7 38.9 
19 Admira Protect -16 46.2 











35 M / 76 W 
-3.23 4.1 
6 









5 1450 NaF Dentifrice  NR 
79 
41.6 
12 M / 67 W 
-14 30 
6 8% Strontium Acetate Dentifrice (Sensodyne Rapid Relief) NR -23.9 59 












44 M / 74 W 
-13.48 22.3 
6 
0.454% wfw stannous fluoride dentifrice (Crest Sensitivity - 
Treatment and Protection) 
NR 
-17.16 28.5 












45 M / 75 W 
-12.47 20.7 
6 0.454% stannous fluoride dentifrice NR -10.82 20.2 











6 M / 75 W 
-53.8 77.1 
11 









8 8% Strontium Acetate Dentifrice (Sensodyne Rapid Relief) NR 
80 
NR 
25 M / 55 W 
-12.05 NC 
11 
8% Arginine Calcium Carbonate Dentifrice (Colgate Sensitive 
Pro-Relief) 
NR -16.86 NC 





9 Oxalic Acid Gel 2% (Pain-Free) 44 
11 
47 
4 M /7 W 
-12.7 38 
9 Oxalic Acid Gel (BisBlock) 43 -19.5 36.3 
18 Resin (Seal and Protect) 44 -28.2 54.9 





12 Glutaraldehyde (Gluma Desensitizer) 11 
27 
22 - 53 
NR 
-27.73 59 
22 Low Power Laser Low Dose 30mW 810 nm (LPLLD) 11 -14.1 60 
22 Low Level Laser High Dose 100mW 810 nm (LPLHD) 11 -32.19 87 
22 + 12 LPLLD + Glutaraldehyde (Gluma Desensitizer) 11 -48.19 79 
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20 Resin-Modified GIC (ClinproTM XT) 70 
20 
42.7 
3 M / 17 W 
-43 84.3 
20 Conventional GIC (Vidrion R) 82 -50 83.3 





1 Placebo Gel 36 
107 
42.94 
55 M / 71 W 
-2.7 3.7 
5 2% Sodium Fluoride Gel (Flugel) 37 -16.8 24.1 
5 + 9 + 14 
5% NaF, 5% Potassium Oxalate and 10% Strontium Chloride 
Gel 
34 -36.1 47.8 










15 Sensi Kill® 62 -21 33.9 
15 Bioactive Glass Gel (Biosilicate® gel) 59 -26 37.7 
15 Bioactive Glass powder (Biosilicate® powder) 59 -40 59.7 










21 Resin-based Sealing Material (Seal and Protect) 103 -22* 76.5* 










22 Low-level laser radiation 4J/cm2 46 -8.9 21.3 





5 Dentifrice (Negative Control) (Colgate Triple Protection) 45 
133 
37.4 




8% Arginine Calcium Carbonate Dentifrice (Sensitive Pro-
Relief) 
43 -14.61 23.1 
15 
5% Calcium Sodium Phosphosilicate (CSPS) Dentifrice 
(Sensodyne ® Repair & Protect) 
45 -15.32 22.3 





12 Glutaraldehyde (control) (Gluma® Desensitizer) 53 
40 
34.63 
11 M / 29 W 
-15 21.4 
25 Biomimetic mineralization system (BIMIN) 58 -17 24.3 





1 Warm water (placebo) 
119 31 
46.9 
13 M / 18 W 
NS VNR 
12 Gulma Dentin Desensitizer SS VNR 
20 Clinpro XT Varnish  SS VNR 





9 BisBlock 43 
64 
46.4 
27 M / 37 W 
-14.5 23.1 
9 SuperSeal 45 -26.4 38.1 
12 + 24 Gluma Desensitizer  45 -17.9 28.5 
15 DeSen 30 -13.4 21.4 
5 + 24 Hurriseal Dentin Desensitizer 52 -21.5 33.7 





2 5 % Potassium Nitrate Gel NR 
54 
25-45 
30 M / 24 W 
SS VNR 
6 0,4 % Stannous fluoride gel  NR SS VNR 
22 LASER GaAlAs 940nm DL  NR SS VNR 





1 Distilled Water (Placebo) NR 
35 
33.3 
10 M / 25 W 
SS VNR 
15 Teethmate AP  NR SS VNR 





12 Glutaraldehyde (Gluma Desensitizer Power Gel) NR 
49 
NR 
16 M / 34 W 
SS VNR 
15 Teethmate Desensitizer  NR SS VNR 
21 NanoSeal NR SS VNR 
21 MS Coat One F NR SS VNR 
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 22 Nd:YAG Laser  1.5W, 10Hz, 100mJ 11 NR SS VNR 
12 + 22 Nd:YAG Laser + Gluma Desensitizer  11 SS VNR 
 
M: men; W: women; NR: not reported; NC: not calculated; CNR: composition not reported; SS: statistically significant; NS: not statistically significant; VNR: 
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Percentage of DH 
reduction between 
baseline and final 
follow-up 










5 2% Sodium Fluoride Solution 64 NR 55 
10 Iontophoresis 2% Sodium Fluoride Solution (Desensitron II) 65 NR 96 
12 5% Glutaraldehyde (GLUMA®) 65 NR 93 





1 Placebo 22 
21 
37 
5 M / 16 W 
3.23 -8.5 
11 
8% Arginine Calcium Carbonate Dentifrice (Colgate Sensitive 
Pro-Relief) 
32 -28.95 52.7 
22 Low Level Laser 685 nm 25 mW (LLL) 41 -27.25 56.8 
11 + 22 LLL followed by DP 29 -25.35 46.2 
11 + 22 DP followed by LLL 32 -24.37 40.6 





1 Not Irradiated (control) 
96 24 
34 
11 M / 13 W 
-0.8 1 
22 Er:YAG LASER 2,940-nm -52.9 63.5 
22 Nd:YAG LASER 1064 nm 1W -72.5 86.5 
22 GaAlAs Diode LASER 808 nm 100mW -38.3 46.2 






Potassium nitrate-based toothpaste (Villevie prophylactic 




13 M / 37 W 
-20 25.3 
11 
8% arginine and calcium carbonate (Colgate Sensitive Pro-
Relief Toothpaste) + 8% arginine, calcium carbonate and 
1,450 ppm fluoride (Colgate Sensitive Pro-Relief Desensitizing 
Paste with Pro-Arginine Technology) 
-32 40.5 





3 3.75% Potassium Chloride Dentifrice (Sensodyne F) 26 
13 
31.2 
6 M / 7 W 
-27.7 34.5 
3 + 22 
Erbium and Diode LASER 100 mW 808 nm + 3.75% Potassium 
Chloride Dentifrice (Sensodyne F) 26 -59.6 73.8 





5 5% NaF Varnish (Duraphat) 
76 19 
NR 
6 M / 13 W 
-22.9 40.1 
9 3% Potassium Oxalate Gel (Oxa-Gel) -23.95 41.8 
19 Self-Etch Adhesive (Clearfil SE Bond) -12.1 25.2 
22 High Intensity Diode LASER 810–830 nm 0.5–4.5 W -19.89 36 





1 Distilled Water (Placebo) 127 
68 
33.8 
36 M /32 W 
1 -1.9 
5 5% NaF Varnish (Copal F) 127 -47 83.9 
11 8% Arginine Calcium Carbonate Dentifrice (Pro-Relief) 127 -45 77.6 
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5 NaF Varnish (Bifluorid 12) NR 
20 
37 
8 M / 12 W 
-50 70.5 
22 Nd:YAG LASER 1.064 2W NR -47.7 67.9 











8% Arginine Calcium Carbonate Dentifrice (Colgate Sensitive 
Pro-Relief) 
-11.7 42.5 
19 Admira Protect -15.4 44.5 











35 M / 76 W 
-8.01 10.2 
6 
0,454% stannous fluoride (Crest® Pro-Health™ Sensitive 
Shield) 
NR -53.31 69.3 












44 M / 74 W 
-23.28 38.5 
6 
0.454% w/w stannous fluoride dentifrice (Crest Sensitivity - 
Treatment and Protection) 
NR -30.30 50.4 












45 M / 75 W 
-19.77 32.9 
6 0.454% stannous fluoride dentifrice NR -23.74 44.3 





9 Oxalic Acid Gel 2% (Pain-Free) 44 
11 
47 
4 M /7 W 
-19.1 57.2 
9 Oxalic Acid Gel (BisBlock) 43 -24.4 45.4 
18 Resin (Seal and Protect) 44 -33 64.2 





20 Resin-Modified GIC (ClinproTM XT) 70 
20 
42.7 
3 M / 17 W 
-44 86.3 
20 Conventional GIC (Vidrion R) 82 -50 83.3 





1 Placebo Gel 36 
107 
42.94 
55 M / 71 W 
-12.2 16.9 
5 2% Sodium Fluoride Gel (Flugel) 37 -26.8 38.5 
5 + 9 + 14 
5% NaF, 5% Potassium Oxalate and 10% Strontium Chloride 
Gel 
34 -45.6 60.3 










15 Sensi Kill® 62 -31 50 
15 Bioactive Glass Gel (Biosilicate® gel) 59 -32 46.4 
15 Bioactive Glass powder (Biosilicate® powder) 59 -44 65.7 





5 Dentifrice (Colgate Triple Protection) 45 
133 
37.4 




8% Arginine Calcium Carbonate Dentifrice (Sensitive Pro-
Relief) 
43 -18.77 29.7 
15 
5% Calcium Sodium Phosphosilicate (CSPS) Dentifrice 
(Sensodyne ® Repair & Protect) 
45 -21.17 30.8 





1 Placebo Dentifrice NR 
149 
39.85 
72 M / 77 W 
-10.8 20.3 
2 5% Potassium Nitrate Dentifrice (SHY) NR -12.3 22.4 
7 3.85% Amine Fluoride Dentifrice (AMFLOR) NR -13.2 24.2 
15 5% Calcium Sodium Phosphosilicate Dentifrice (SHY‐NM) NR -17.7 31.9 
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 2 5% Potassium Nitrate Dentifrice (SHY) NR 58 M / 52 W -9.1 13.9 
15 5% Calcium Sodium Phosphosilicate Dentifrice (SHY-NH) NR -24.6 34.3 





1 Water (Placebo) NR 
105 
42 
48 M / 57 W 
-1.24 2.2 
5 Fluoride Dentifrice (Colgate Cavity Protection Regular) NR -3.52 6.4 
15 15% Nano Hydroxyapatite Dentifrice (PrevDent) NR -16.8 29.9 





1 Glycerin (placebo) NR 
105 
42 
40 M / 65 W 
1.86 -3.3 
5 NaF Dentifrice (Colgate Cavity Gel) (Positive Control) NR -3.87 6.8 
15 2% Nano-hydroxyapatite Dentifrice (Cavex Bite&White) NR -16.37 27.5 





1 Negative Control Dentifrice Without NovaMin NR 
71 
44.1 
34 M / 41 W 
NR 15.2 
14 Strontium Chloride Dentifrice (Leng Suan Ling Toothpaste) NR NR 14.7 
15 5% NovaMin Dentifrice  NR NR 17.6 
 





1 Placebo Dentifrice NR 
66 
38.8 
12 M / 54 W 
-2.6 5 
15 2.5% Novamin Dentifrice NR -5.1 9 
15 7.5% Novamin Dentifrice NR -13.9 26 





2 5% Potassium Nitrate Dentifrice (RA Thermoseal) NR 
240 
20 - 60 
93 M / 67 W 
-8.5 11.8 
14 3-10% Strontium Chloride Dentifrice (Thermoseal®) NR -19.2 26.3 
15 
5% Calcium Sodium Phosphosilicate (Novamin) Dentifrice 
(Vantej) 
NR -30.2 41.9 
16 Herbal Dentifrice (Wheezal dental cream) NR -8.5 12 










5 Dentifrice without Potassium Nitrate (ProSensitive) NR -11.9 16.8 





2 5% KNO3 Dentifrice (Sensodyne® Original) NR 
226 
36.3 
73 M /  
153 W 
-12.2 23.9 
5 NaF Dentifrice (Crest Cavity Protection Regular) NR -7.5 14.6 
2 + 5 
Potassium Oxalate Mouthrinse (Listerine Advanced Defense 
Sensitive) + NaF Dentifrice (Crest Cavity Protection Regular) NR -10.7 21.2 





1 Control Dentifrice (CNR) NR 
30 20 - 50 
0.3 -0.5 
2 5% Potassium Nitrate Dentifrice NR -0.5 0.9 
15 5% Calcium Sodium Phosphosilicate Dentifrice (Novamin) NR -19.6 34 





2 5% Potassium Nitrate Dentifrice (Sensodent K) NR 
120 
31.7 
60 M / 60 W 
-20.5 35 
6 0.4% Stannous Fluoride Dentifrice NR -17.3 29.7 
15 7.5% Calcium Sodium Phosphosilicate (Novamin) Dentifrice 
(Soothe RX 
NR -25.8 45 












21 Desensitizing Agent (Seal and Protect, Dentsply) NR 48.21 
19 M / 53 W 
-50.15 81.8 
23 Desensitizing Toothpaste (Colgate Sensitive Fresh Stripe) NR -15.67 27.8 















8% Arginine Calcium Carbonate Dentifrice (Colgate Sensitive 
Pro-Relief) 
NR 
37 M / 41 W 
-7.6 17.5 
Ko et al. 2014
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 Parallel 
22 LASER Toothbrush (635 nm e 6 mW) NR 
86 
40.65 
29 M / 57 W 
-19 32.8 
25 LED Toothbrush (635 nm e12.9 µW) NR -12 18.8 






Dentifrice containing 1400ppm fluoride as AMFP (Chinese 




17 M /  
117 W 
SS VNR 
15 2,5 % CSPS (4μm) and 1450 ppm fluoride as NaF NR SS VNR 
15 5 % CSPS (4μm) and 1450 ppm fluoride as NaF NR SS VNR 
15 5 % CSPS (14μm) and 1450 ppm fluoride as NaF (Novamin) NR SS VNR 
15 
5 % CSPS (14μm) and 1450 ppm fluoride as NaF (UK 
Sensodyne Repair and Protect) 
NR SS VNR 





2 Potassium nitrate dentifrice NR 48 18 - 67 
NR 
NS VNR 




M: men; W: women; NR: not reported; NC: not calculated; CNR: composition not reported; SS: statistically significant; NS: not statistically significant; VNR: 
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Percentage of DH 
reduction between 
baseline and final  
follow-up 





1 NaF Placebo 64 
48 
41 
22 M / 26W 
-2.4 3.7 
1 LASER Placebo 64 -2.4 4.0 
5 NaF Varnish 58 -53.5 79.1 
22 GaAlAs Diode LASER 500mW 810 nm 58 -49.8 79 










5 2% Sodium Fluoride Solution 64 NR 34 
10 Iontophoresis 2% Sodium Fluoride Solution (Desensitron II) 65 NR 85 
12 5% Glutaraldehyde (GLUMA®) 65 NR 75 





1 Water (placebo) 
150 50 
32.4 
32 M / 18 W 
-32.6 49.8 
9 Oxalic Acid (BisBlock) -19.4 31.2 
12 Glutaraldehyde (Gluma Desensitizer PowerGel) -48.2 74.6 





1 Placebo 22 
21 
37 
5 M / 16 W 
3.09 -8.2 
11 
8% Arginine Calcium Carbonate Dentifrice (Colgate Sensitive 
Pro-Relief) 
32 -34.2 62.3 
22 Low Level Laser 685 nm 25 mW (LLL) 41 -33.9 70.6 
11 + 22 LLL followed by DP 29 -26.19 48.8 
11 + 22 DP followed by LLL 32 -37.06 61.7 





1 Control (no treatment) 7 
28 NR 
-24.6 NC 
22 Er:YAG LASER  (0,64W/5.9 J/cm2) 7 -31.6 NC 
22 Er,Cr:YSGG LASER  (0.25 W/4.4 J/cm2) 7 -22.6 NC 
22 Er,Cr:YSGG LASER (0.50 W/ 8.9 J/cm2) 7 -16.7 NC 





1 Control (no treatment) 
174 51 
44 
22 M / 29 W 
-3 4.3 
22 Er,Cr:YSGG LASER  2780 nm 0,25W -61 84.7 
22 GaAlAs Diode LASER 810 nm  -59 83.1 





1 LASER Er, Cr:YSGG without emission (Placebo) 
146 42 
33.8 -7.5 10.9 
22 LASER Er, Cr:YSGG 0,25W 18 M / 24 W -57 81.2 





1 Not Irradiated (control) 
96 24 
34 
11 M / 13 W 
0 0 
22 Er:YAG LASER 2,940-nm -52.9 63.5 
22 Nd:YAG LASER 1064 nm 1W -73 87.1 
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Potassium nitrate-based toothpaste (Villevie prophylactic 




13 M / 37 W 
-32 40.5 
11 
8% arginine and calcium carbonate (Colgate Sensitive Pro-
Relief Toothpaste) + 8% arginine, calcium carbonate and 
1,450 ppm fluoride (Colgate Sensitive Pro-Relief Desensitizing 
Paste with Pro-Arginine Technology) 
-43 54.4 
 





3 3.75% Potassium Chloride Dentifrice (Sensodyne F) 26 
13 
31.2 
6 M / 7 W 
-29.2 36.3 
3 + 22 
Erbium and Diode LASER 100 mW 808 nm + 3.75% Potassium 
Chloride Dentifrice (Sensodyne F) 
26 -59.6 73.8 





5 5% NaF Varnish (Duraphat) 
76 19 
NR 
6 M / 13 W 
-31.89 55.8 
9 3% Potassium Oxalate Gel (Oxa-Gel) -25.16 43.9 
19 Self-Etch Adhesive (Clearfil SE Bond) -18.05 37.6 
22 High Intensity Diode LASER 810–830 nm 0.5–4.5 W -19.84 35.9 





1 Distilled Water (Placebo) 127 
68 
33.8 
36 M /32 W 
0 0 
5 5% NaF Varnish (Copal F) 127 -50 89.3 
11 8% Arginine Calcium Carbonate Dentifrice (Pro-Relief) 127 -49 84.5 
12 5% Glutaraldehyde (Gluma Desensitizer) 127 -54 93.1 










19 Admira Protect 28 -14 56 
19 PRG-Barrier Coat 28 -13 43.3 





5 4 a 6 % NaF Varnish (Flor-Opal® Varnish) 31 
46 
NR 
19 M / 27 W 
-20 50 
18 Flow Resin (Vertice Flow) 28 -25 62.5 
19 Adhesive (Clearfil Protect Bond) 30 -20 50 
21 Sealant (Universal Dentine Sealant) 27 -30 60 





5 2% NaF solution 65 
24 
38 
8 M / 16 W 
-19 29.7 
12 Glutaraldehyde (Gluma desensitizer) 67 -37 56.1 
22 Diode LASER  320 nm 69 -45 62.5 
5 + 22 NaF + Diode LASER 61 -48 69.6 





5 NaF Varnish (Bifluorid 12) NR 
20 
37 
8 M / 12 W 
-50.5 71.2 
22 Nd:YAG LASER 1.064 2W NR -46.2 65.8 











8% Arginine Calcium Carbonate Dentifrice (Colgate Sensitive 
Pro-Relief) 
-9.5 34.5 
19 Admira Protect -15.6 45.1 





5 NaF Dentifrice (Crest® Decay Prevention Toothpaste) NR 
19 
43.5 
1 M / 18 W 
-24.9 72 
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9 Oxalic Acid Gel 2% (Pain-Free) 44 
11 
47 
4 M /7 W 
-21.6 64.7 
9 Oxalic Acid Gel (BisBlock) 43 -33.7 62.8 
18 Resin (Seal and Protect) 44 -43.4 84.4 





12 Glutaraldehyde (Gluma Desensitizer) 18 
 
18 - 35 
8 M / 12 W 
-63 86.3 
19 Universal Adhesive (Single Bond Universal) 18 20 -52 70.3 
12 + 19 










12 Glutaraldehyde (Gluma Desensitizer) 11 
27 
22 - 53 
NR 
-39.48 84 
22 Low Power Laser Low Dose 30mW 810 nm (LPLLD) 11 -13.16 56 
22 Low Level Laser High Dose 100mW 810 nm (LPLHD) 11 -32.19 87 
22 + 12 LPLLD + Glutaraldehyde (Gluma Desensitizer) 11 -53.68 88 
22 + 12 LPLHD + Glutaraldehyde (Gluma Desensitizer) 11 -52.65 81 





12 5% Glutaraldehyde (Gluma Desensitizer) NR 
250 
20 - 55 
NR 
-33.8 49.1 
13 1% Chlorhexidine (Cervitec) NR -49.7 70 
 










19 Total Etch Adhesive with Glutaraldehyde (Gluma 2 Bond) -46 83.6 
20 Resin-Modified GIC (ClinproTM XT) -50 84.7 





20 Resin-Modified GIC (ClinproTM XT) 70 
20 
42.7 
3 M / 17 W 
-42 82.4 
20 Conventional GIC (Vidrion R) 82 -52 86.7 





1 Placebo Gel 36 
107 
42.94 
55 M / 71 W 
-15.6 21.6 
5 2% Sodium Fluoride Gel (Flugel) 37 -30.9 44.3 
5 + 9 + 14 5% NaF, 5% Potassium Oxalate and 10% Strontium Chloride  34 -56.7 75 










15 Sensi Kill® 62 -45 72.6 
15 Bioactive Glass Gel (Biosilicate® gel) 59 -34 49.3 
15 Bioactive Glass powder (Biosilicate® powder) 59 -58 86.6 





5 Dentifrice (Colgate Triple Protection) 45 
 
37.4 




8% Arginine Calcium Carbonate Dentifrice (Sensitive Pro-
Relief) 
43 133 -25.87 41 
15 
5% Calcium Sodium Phosphosilicate (CSPS) Dentifrice 









12 Glutaraldehyde (control) (Gluma® Desensitizer) 53 
40 
34.63 
11 M / 29 W 
-17 24.3 
25 Biomimetic mineralization system (BIMIN) 58 -28 40 





1 Water (Placebo) NR 
105 
42 
48 M / 57 W 
-3.21 5.6 
5 Fluoride Dentifrice (Colgate Cavity Protection Regular) NR -4.66 8.5 
15 15% Nano Hydroxyapatite Dentifrice (PrevDent) NR -20.17 35.9 
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77
 5 NaF Dentifrice (Colgate Cavity Gel) (Positive Control) NR 40 M / 65 W -4.79 8.4 
15 2% Nano-hydroxyapatite Dentifrice (Cavex Bite&White) NR -18.2 30.5 





1 Placebo Dentifrice NR 
66 
38.8 
12 M / 54 W 
-6.8 14 
15 2.5% Novamin Dentifrice NR -14.5 28 
15 7.5% Novamin Dentifrice NR -21.5 43 





2 5% Potassium Nitrate Dentifrice (RA Thermoseal) NR 
240 
20 - 60 
93 M / 67 W 
-43.3 59.9 
14 3-10% Strontium Chloride Dentifrice (Thermoseal ®) NR -43.7 59.9 
15 
5% Calcium Sodium Phosphosilicate (Novamin) Dentifrice 
(Vantej) 
NR -64 88.9 
16 Herbal Dentifrice (Wheezal dental cream) NR -35 49.4 










5 Dentifrice without Potassium Nitrate (ProSensitive) NR -18.6 26.3 





2 5% KNO3 Dentifrice (Sensodyne® Original) NR 
226 
36.3 
73 M / 
153 W 
-22.6 44.3 
5 NaF Dentifrice (Crest Cavity Protection Regular) NR -11.6 22.5 
2 + 5 
Potassium Oxalate Mouthrinse (Listerine Advanced Defense 
Sensitive) + NaF Dentifrice (Crest Cavity Protection Regular) 
NR -21.6 42.8 





1 Control Dentifrice (CNR) NR 
30 
20 - 50 
NR 
-2.6 4.6 
2 5% Potassium Nitrate Dentifrice NR -11 19.3 
15 5% Calcium Sodium Phosphosilicate Dentifrice (Novamin) NR -37.8 65.5 





2 5% Potassium Nitrate Dentifrice (Sensodent K) NR 
120 
31.7 
60 M / 60 W 
-28.7 49.1 
6 0.4% Stannous Fluoride Dentifrice NR -26.5 45.5 
15 
7.5% Calcium Sodium Phosphosilicate (Novamin) Dentifrice 
(Soothe RX) 
NR -39.3 68.6 
 





8 8% Strontium Acetate Dentifrice (Sensodyne Rapid Relief) NR 
78 
26.45 
37 M / 41 W 
-17.3 40.1 
11 
8% Arginine Calcium Carbonate Dentifrice (Colgate Sensitive 
Pro-Relief) 
NR -15.7 36.2 





22 LASER Toothbrush (635 nm e 6 mW) NR 
86 
40.65 
29 M / 57 W 
-35 60.3 






1 Air Delivery (Control) 35 
35 
32.29 
17 M / 18 W 
-18.53 36.7 
17 Ozone Delivery 56 -12.91 25.5 





5 NaF Varnish 22600 ppm F (Duraphat) 45 
28 
18 - 60 
7 M / 21 W 
-28.1 NC 
11 8% Arginine Calcium Carbonate Dentifrice (Pro-Relief) 26 -41.3 NC 
2 + 5 + 15 
20% Hydroxyapatite and Potassium Nitrate, NaF Dentifrice 
9000 ppm F (Desensitize Nano-P) 
30 -40.8 NC 
2 + 5 + 15 
10% Hidroxyapatite, Potassium Nitrate, NaF Dentifrice 900 
ppm F (experimental home-care paste) 
22 -44.8 NC 
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27 M / 92 W 
-8.06 13.8 
6 0,454% Stannous Fluoride Dentifrice NR -20.2 34.7 




Parallel 5 + 15 
5% Calcium Sodium Phosphosilicate and 1426 ppm fluoride as 
NaF (GSKCH) 
NR 296 41.8 




5 + 15 
5% Calcium Sodium Phosphosilicate and 1426 ppm fluoride as 









1 Warm water (placebo) 
119 31 
46.9 
13 M / 18 W 
NS VNR 
12 Gulma Dentin Desensitizer SS VNR 
20 Clinpro XT Varnish  SS VNR 





9 BisBlock 43 
64 
46.4 
27 M / 37 W 
-28.2 45,0 
9 SuperSeal 45 -31.5 45.5 
12 + 24 Gluma Desensitizer  45 -29.3 46.6 
15 DeSen 30 -11.7 18.7 
5 + 24 Hurriseal Dentin Desensitizer 52 -24.6 38.6 






Dentifrice containing 1400ppm fluoride as AMFP (Chinese 




17 M / 
117 W 
SS VNR 
15 2,5 % CSPS (4μm) and 1450 ppm fluoride as NaF NR SS VNR 
15 5 % CSPS (4μm) and 1450 ppm fluoride as NaF NR SS VNR 
15 5 % CSPS (14μm) and 1450 ppm fluoride as NaF (Novamin) NR SS VNR 
15 
5 % CSPS (14μm) and 1450 ppm fluoride as NaF (UK 
Sensodyne Repair and Protect) 
NR SS VNR 










21 - 68 
35 M / 45 W 
SS VNR 
10 + 11 
8.0% arginine-calcium carbonate (Colgate® Sensitive Pro-
ReliefTM) + iontophoresis 
NR SS VNR 





2 Potassium nitrate dentifrice NR 
48 
18 - 67 
NR 
SS VNR 
25 10 % Casein Phosphopeptide-Amorphius calcium phosphate NR SS VNR 





1 Distilled Water (Placebo) 
 35 
33.3 
10 M / 25 W 
SS VNR 









12 Glutaraldehyde (Gluma Desensitizer Power Gel) NR 
49 
NR 
16 M / 34 W 
SS VNR 
15 Teethmate Desensitizer  NR SS VNR 
21 NanoSeal NR SS VNR 
21 MS Coat One F NR SS VNR 










22 Nd:YAG Laser  1.5W, 10Hz, 100mJ 11 SS VNR 
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M: men; W: women; NR: not reported; NC: not calculated; CNR: composition not reported; SS: statistically significant; NS: not statistically significant; VNR: 
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Percentage of DH 
reduction between 
baseline and final  
follow-up 





1 NaF Placebo 64 
48 
41 
22 M / 26W 
-3 4.6 
1 LASER Placebo 64 -0.3 0.5 
5 NaF Varnish 58 -38.4 56.8 
22 GaAlAs Diode LASER 500mW 810 nm 58 -51.4 81.6 










5 2% Sodium Fluoride Solution 64 NR 22 
10 Iontophoresis 2% Sodium Fluoride Solution (Desensitron II) 65 NR 74 
12 5% Glutaraldehyde (GLUMA®) 65 NR 52 





1 Water (placebo) 
150 50 
32.4 
32 M / 18 W 
-29.4 45 
9 Oxalic Acid (BisBlock) -16 25.7 
12 Glutaraldehyde (Gluma Desensitizer PowerGel) -45.6 70.6 





1 Placebo 22 
21 
37 
5 M / 16 W 
2.94 -7.8 
11 
8% Arginine Calcium Carbonate Dentifrice (DP) (Colgate 
Sensitive Pro-Relief) 
32 -35.9 65.4 
22 Low Level Laser 685 nm 25 mW (LLL) 41 -34.57 72 
11 + 22 LLL followed by DP 29 -29.98 54.6 
11 + 22 DP followed by LLL 32 -41.85 69.6 





1 Control (no treatment) 
174 51 
44 
22 M / 29 W 
-5 7.2 
22 Er,Cr:YSGG LASER  2780 nm 0,25W -62 86.1 
22 GaAlAs Diode LASER 810 nm  -60 84.5 





1 LASER Er, Cr:YSGG without emission (Placebo) 
146 42 
33.8 
18 M / 24 W 
-7.9 11.5 
22 LASER Er, Cr:YSGG 0,25W -56.7 80.8 





1 Not Irradiated (control) 
96 24 
34 
11 M / 13 W 
-2.5 3 
22 Er:YAG LASER 2,940-nm -53.7 64.5 
22 Nd:YAG LASER 1064 nm 1W -72.5 86.5 
22 GaAlAs Diode LASER 808 nm 100mW -40.4 48.7 





Potassium nitrate-based toothpaste (Villevie prophylactic 
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11 
8% arginine and calcium carbonate (Colgate Sensitive Pro-
Relief Toothpaste) + 8% arginine, calcium carbonate and 
1,450 ppm fluoride (Colgate Sensitive Pro-Relief Desensitizing 
Paste with Pro-Arginine Technology) 
-57 72,2 





3 3.75% Potassium Chloride Dentifrice (Sensodyne F) 26 
13 
31.2 
6 M / 7 W 
-38.9 48.4 
3 + 22 
Erbium and Diode LASER 100 mW 808 nm + 3.75% Potassium 
Chloride Dentifrice (Sensodyne F) 
26 -60 74.3 
 





5 5% NaF Varnish (Duraphat) 
76 19 
NR 
6 M / 13 W 
-34.37 60.1 
9 3% Potassium Oxalate Gel (Oxa-Gel) -30.58 53.3 
19 Self-Etch Adhesive (Clearfil SE Bond) -24.37 50.7 
22 High Intensity Diode LASER 810–830 nm 0.5–4.5 W -34.07 61.7 





5 4 a 6 % NaF Varnish (Flor-Opal® Varnish) 31 
46 
NR 
19 M / 27 W 
-10 25 
18 Flow Resin (Vertice Flow) 28 -20 50 
19 Adhesive (Clearfil Protect Bond) 30 -20 50 
21 Sealant (Universal Dentine Sealant) 27 -30 60 





9 Potassium Binoxalate Gel (D/Sens Crystal) 40 
20 
25 - 55 
10 M / 10 W 
-70 89.7 
22 Nd:YAG LASER, 1W 40 -69.2 93.5 
Patil et al. 2015
62
 Parallel 
12 Glutaraldehyde (Gluma Desensitizer) 18 
 
18 - 35 
8 M / 12 W 
-64 87.7 
19 Universal Adhesive (Single Bond Universal) 18 20 -54 73 
12 + 19 










12 Glutaraldehyde (Gluma Desensitizer) 11 
27 
22 - 53 
NR 
-43.71 93 
22 Low Power Laser Low Dose 30mW 810 nm (LPLLD) 11 -21.42 89 
22 Low Level Laser High Dose 100mW 810 nm (LPLHD) 11 -27.38 74 
22 + 12 LPLLD + Glutaraldehyde (Gluma Desensitizer) 11 -53.07 87 
22 + 12 LPLHD + Glutaraldehyde (Gluma Desensitizer) 11 -52 80 





12 5% Glutaraldehyde (Gluma Desensitizer) NR 
250 
20 - 55 
NR 
-39.4 57.2 
13 1% Chlorhexidine (Cervitec) NR -52.9 74.5 










19 Total Etch Adhesive with Glutaraldehyde (Gluma 2 Bond) -45 81.8 
20 Resin-Modified GIC (ClinproTM XT) -49 83.1 





20 Resin-Modified GIC (ClinproTM XT) 70 
20 
42.7 
3 M / 17 W 
-45 88.2 
20 Conventional GIC (Vidrion R) 82 -55 91.7 









15 Sensi Kill® 62 NR -54 87.1 
15 Bioactive Glass Gel (Biosilicate® gel) 59 NR -38 55.1 
15 Bioactive Glass powder (Biosilicate® powder) 59 
 
-64 95.5 
Hall et al. Parallel 5 Dentifrice (Colgate Triple Protection) 45 
 















8% Arginine Calcium Carbonate Dentifrice (Sensitive Pro-
Relief) 
43 133 




5% Calcium Sodium Phosphosilicate (CSPS) Dentifrice 









12 Glutaraldehyde (control) (Gluma® Desensitizer) 53 
40 
34.63 
11 M / 29 W 
-23 32.9 
25 Biomimetic mineralization system (BIMIN) 58 -23 32.9 





1 Placebo Dentifrice NR 
149 
39.85 
27 M / 77 W 
-17.6 33.1 
2 5% Potassium Nitrate Dentifrice (SHY) NR -31.3 57.1 
7 3.85% Amine Fluoride Dentifrice (AMFLOR) NR -33.7 61.7 
15 5% Calcium Sodium Phosphosilicate Dentifrice (SHY‐NM) NR -36.7 66.1 





1 Placebo Dentifrice NR 
110 
39.4 
58 M / 52 W 
-25.7 40.2 
2 5% Potassium Nitrate Dentifrice (SHY) NR -29.1 44.3 
15 5% Calcium Sodium Phosphosilicate Dentifrice (SHY-NH) NR -52 72.5 
 





1 Negative Control Dentifrice Without NovaMin NR 
71 
44.1 
34 M / 41 W 
NR 21.3 
14 Strontium Chloride Dentifrice (Leng Suan Ling Toothpaste) NR NR 10.9 
15 5% NovaMin Dentifrice  NR NR 34.8 





1 Placebo Dentifrice NR 
66 
38.8 
12 M / 54 W 
-14.5 28 
15 2.5% Novamin Dentifrice NR -15.5 30 
15 7.5% Novamin Dentifrice NR -27.4 55 





2 5% Potassium Nitrate Dentifrice (RA Thermoseal) NR 
240 
20 - 60 
93 M / 67 W 
-8.5 11.8 
14 3-10% Strontium Chloride Dentifrice (Thermoseal ®) NR -19.2 26.3 
15 
5% Calcium Sodium Phosphosilicate (Novamin) Dentifrice 
(Vantej) 
NR -30.2 41.9 
16 Herbal Dentifrice (Wheezal dental cream) NR -8.5 12 





2 5% Potassium Nitrate Dentifrice (Sensodent K) NR 
120 
31.7 
60 M / 60 W 
-49 83.8 
6 0.4% Stannous Fluoride Dentifrice NR -50.8 87.1 
15 
7.5% Calcium Sodium Phosphosilicate (Novamin) Dentifrice 
(Soothe RX) 
NR -50 87.3 











19 M / 53 W 
-6.22 11 
21 Desensitizing Agent (Seal and Protect, Dentsply) NR -51.41 83.8 
23 Desensitizing Toothpaste (Colgate Sensitive Fresh Stripe) NR -25.04 44.3 





8 8% Strontium Acetate Dentifrice (Sensodyne Rapid Relief) NR 
78 
26.45 
37 M / 41 W 
-25.4 58.9 
11 
8% Arginine Calcium Carbonate Dentifrice (Colgate Sensitive 
Pro-Relief) 






1 Air Delivery (Control) 35 
35 
32.29 
17 M / 18 W 
-27.66 54.8 
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5 NaF Varnish 22600 ppm F (Duraphat) 45 
28 
18 - 60 
7 M / 21 W 
-25.3 NC 
11 8% Arginine Calcium Carbonate Dentifrice (Pro-Relief) 26 -52.1 NC 
2 + 5 + 15 
20% Hydroxyapatite and Potassium Nitrate, NaF Dentifrice 
9000 ppm F (Desensitize Nano-P) 
30 -45.2 NC 
2 + 5 + 15 
10% Hydroxyapatite, Potassium Nitrate, NaF Dentifrice 900 
ppm F (experimental home-care paste) 
22 -47.3 NC 











27 M / 92 W 
-14.58 25 
6 0,454% Stannous Fluoride Dentifrice NR -36.4 62.5 





5 + 15 





51 M / 
253 W 
-22.04 41.4 
5 + 15 
5% Calcium Sodium Phosphosilicate and 1426 ppm fluoride as 
SMFP (Sensodyne Repair and Protect) 
NR -24.47 43.8 





1 Placebo Dentifrice NR 
120 
25 - 60 
73 M / 72 W 
-11.3 14.4 
2 5% Potassium Nitrate Dentifrice NR -44 55.5 
2 + 16 
Herbal Dentifrice with Potassium Nitrate and Spinacia 
oleracia NR -42.7 52.7 





1 Placebo Dentifrice NR 
60 
42.1 
33 M / 27 W 
-9.6 13.5 
16 
Herbal Dentifrice Potassium Nitrate and Spinacia oleracia (Hi 
Ora K) 
NR -34 46.1 
 





1 Control cream without nano-HAP NR 
198 
47.61 
46 M / 
152 W 
NR 50.67 
1 Control toothpaste without nano-HAP NR NR 47.19 
5 Toothpaste containing 1500 ppm fluoride as MFP NR NR 51.59 
15 Toothpaste containing Novamin® technology NR NR 51.44 
15 Toothpaste with nano-HAP (high concentration) NR NR 41.59 
15 Toothpaste with nano-HAP (low concentration) NR NR 38.64 
15 Toothpaste with nano-HAP (medium concentration) NR NR 58.65 
15 Cream with nano-HAP (higher concentration) NR NR 38.99 
2 + 15 Toothpaste with nano-HAP and (Potassium Nitrate) KNO3 NR NR 53.16 





5 Pepsodent toothpaste NR 
30 




SHY NM™ tooth paste with 5% calcium sodium 
phosphosilicate 
NR -22.27 38.8 





12 Glutaraldehyde (Gluma Desensitizer)  88 
22 
39 
7 M / 15 W 
-38 84.4 
22 LASER Er:YAG 655 nm/1 mW 62 -39 86.7 





9 BisBlock 43 
64 
46.4 
27 M / 37 W 
-27.2 43.4 
9 SuperSeal 45 -29.3 42.3 
12 + 24 Gluma Desensitizer  45 -26.5 42.1 
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5 + 24 Hurriseal Dentin Desensitizer 52 -21.5 33.7 






Dentifrice containing 1400ppm fluoride as AMFP (Chinese 




17 M / 117 
W 
SS VNR 
15 2,5 % CSPS (4μm) and 1450 ppm fluoride as NaF NR SS VNR 
15 5 % CSPS (4μm) and 1450 ppm fluoride as NaF NR SS VNR 
15 5 % CSPS (14μm) and 1450 ppm fluoride as NaF (Novamin) NR SS VNR 
15 
5 % CSPS (14μm) and 1450 ppm fluoride as NaF (UK 
Sensodyne Repair and Protect) 
NR SS VNR 





2 Potassium nitrate dentifrice NR 
48 
18 - 67 
NR 
SS VNR 
25 10 % Casein Phosphopeptide-Amorphius calcium phosphate NR SS VNR 





1 Distilled Water (Placebo) NR 
35 
33.3 
10 M / 25 W 
SS VNR 
15 Teethmate AP  NR SS VNR 





12 Glutaraldehyde (Gluma Desensitizer Power Gel) NR 
49 
NR 
16 M / 34 W 
SS VNR 
15 Teethmate Desensitizer  NR SS VNR 
21 NanoSeal NR SS VNR 
21 MS Coat One F NR SS VNR 










22 Nd:YAG Laser  1.5W, 10Hz, 100mJ 11 SS VNR 
12 + 22 Nd:YAG Laser + Gluma De- sensitizer  11 SS VNR 
 
M: men; W: women; NR: not reported; NC: not calculated; CNR: composition not reported; SS: statistically significant; NS: not statistically significant; VNR: 
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Percentage of DH 
reduction between 
baseline and final  
follow-up 





1 NaF Placebo 64 
48 
41 
22 M / 26W 
-1.7 2.6 
1 LASER Placebo 64 -0.6 1.0 
5 NaF Varnish 58 -33.5 49.6 
22 GaAlAs Diode LASER 500mW 810 nm 58 -51.6 81.9 





1 Water (placebo) 
150 50 
32.4 
32 M / 18 W 
-26 39.8 
9 Oxalic Acid (BisBlock) -15.6 25.1 
12 Glutaraldehyde (Gluma Desensitizer PowerGel) -42.4 65.6 





5 2% NaF solution 65 
24 
38 
8 M / 16 W 
-3 4.7 
12 Glutaraldehyde (Gluma desensitizer) 67 -18 27.3 
22 Diode LASER  320 nm 69 -34 47.2 
5 + 22 NaF + Diode LASER 61 -42 60.9 





9 Potassium Binoxalate Gel (D/Sens Crystal) 40 
20 
25 - 55 
10 M / 10 W 
-75.2 96.4 
22 Nd:YAG LASER, 1W 40 -72.4 97.8 





12 Glutaraldehyde (Gluma Desensitizer) 11 
27 
22 - 53 
NR 
-30.55 65 
22 Low Power Laser Low Dose 30mW 810 nm (LPLLD) 11 -16.69 71 
22 Low Level Laser High Dose 100mW 810 nm (LPLHD) 11 -32.19 87 
22 + 12 LPLLD + Glutaraldehyde (Gluma Desensitizer) 11 -49.41 81 
22 + 12 LPLHD + Glutaraldehyde (Gluma Desensitizer) 11 -53.95 83 










19 Total Etch Adhesive with Glutaraldehyde (Gluma 2 Bond) -46 83.6 
20 Resin-Modified GIC (ClinproTM XT) -52 88.1 





20 Resin-Modified GIC (ClinproTM XT) 70 
20 
42.7 
3 M / 17 W 
-47 92.2 
20 Conventional GIC (Vidrion R) 82 -58 96.7 










15 Sensi Kill® 62 -55 88.7 
15 Bioactive Glass Gel (Biosilicate® gel) 59 -38 55.1 
15 Bioactive Glass powder (Biosilicate® powder) 59 -66.1 98.7 










21 Resin-based Sealing Material (Seal and Protect) 103 -17.75* 61.7* 











19 M / 53 W 
-8.52 15.1 
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23 Desensitizing Toothpaste (Colgate Sensitive Fresh Stripe) NR -27.5 48.7 





12 Glutaraldehyde (Gluma Desensitizer)  88 
22 
39 
7 M / 15 W 
-44 97.8 
22 LASER Er:YAG 655 nm/1 mW 62 -40 88.9 





2 5% Potassium Nitrate Gel NR 
54 
25-45 
30 M / 24 W 
SS VNR 
6 0,4 % Stannous fluoride gel  NR SS VNR 
22 LASER GaAlAs 940nm DL  NR SS VNR 





1 Distilled Water (Placebo) NR 
35 
33.3 
10 M / 25 W 
SS VNR 
15 Teethmate AP  NR SS VNR 





12 Glutaraldehyde (Gluma Desensitizer Power Gel) NR 
49 
NR 
16 M / 34 W 
SS VNR 
15 Teethmate Desensitizer  NR SS VNR 
21 NanoSeal NR SS VNR 
21 MS Coat One F NR SS VNR 










22 Nd:YAG Laser  1.5W, 10Hz, 100mJ 11 SS VNR 
12 + 22 Nd:YAG Laser + Gluma De- sensitizer  11 SS VNR 
 
M: men; W: women; NR: not reported; NC: not calculated; CNR: composition not reported; SS: statistically significant; NS: not statistically significant; VNR: 
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Percentage of DH 
reduction between 
baseline and final  
follow-up 





9 Potassium Binoxalate Gel (D/Sens Crystal) 40 
20 
25 - 55 
10 M / 10 W 
-52.4 67.2 
22 Nd:YAG LASER, 1W 40 -58.8 79.5 





12 Glutaraldehyde (Gluma Desensitizer) 13 
32 
22 - 53 
NR 
-47 100 
22 LASER Low Power Low Dose (LPLD) 810 nm 30 mW 13 -14 59.6 
22 LASER Low Power High Dose (LPHD) 810nm 100 mW 13 -29.5 79.7 
22 Nd:YAG LASER 1064 nm 1 W 13 -25 54.3 
22 + 22 LPLD + Nd:YAG LASER 1064 nm 13 -31.5 74.1 
22 + 22 LPHD + Nd:YAG LASER 1064 nm 13 -54.5 89.3 
12 + 22 LPLD + Glutaraldehyde (Gluma Desensitizer) 13 -60 98.4 
12 + 22 LPHD + Glutaraldehyde (Gluma Desensitizer) 13 -46 70.8 
22 + 12 Nd:YAG LASER + Glutaraldehyde (Gluma Desensitizer) 13 -46 78 





12 Glutaraldehyde (Gluma® Desensitizer) 53 
40 
34.63 
11 M / 29 W 
-20 28.6 
25 Biomimetic mineralization system (BIMIN) 58 -21 30 
 
M: men; W: women; NR: not reported; NC: not calculated; CNR: composition not reported; SS: statistically significant; NS: not statistically significant; VNR: 
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Table 4 – P values referent to the statistical comparison between DH reduction of each 




















n.d.: not determined due to insufficient number of studies found in the literature. In the cases where 










 Treatment 1 day 2 -7 days 8 -15 days 15 days – 1 
month 
1 – 3 months 
2 Potassium nitrate 1.000 0.372 0.765 0.248 0.001 
3 Potassium chloride n.d.  n.d. n.d. n.d. n.d. 
4 Potassium fluoride n.d. n.d. n.d. n.d. n.d. 
5 Sodium fluoride 0.364 0.207 0.156 0.120 0.866 
6 Stannous fluoride 1.000 0.998 0.014 0.977 0.996 
7 Amine fluoride n.d. n.d. n.d. n.d. n.d. 
8 Strontium acetate 1.000 0.957 n.d. 1.000 n.d. 
9 Oxalates 0.194 0.999 0.399 0.995 0.088 
10 Iontophoresis n.d. n.d. n.d. n.d. n.d. 
11 Arginine 0.990 1.000 0.070 0.145 0.038 
12 Glutaraldehyde + HEMA < 0.001 0.015 n.d. < 0.001 0.002 
13 Chlorhexidine n.d. n.d. n.d. n.d. n.d. 
14 Strontium Chloride n.d. n.d. n.d. n.d. n.d. 
15 Hydroxyapatite n.d. 0.804 0.010 0.008 < 0.001 
16 Herbal n.d. n.d. n.d. n.d. 0.139 
17 Ozone n.d. n.d. n.d. n.d. n.d. 
18 Composite resins 0.577 0.889 n.d. 0.482 n.d. 
19 Adhesive systems 0.063 0.950 0.987 0.168 0.027 
20 Glass ionomer cements 0.012 0.127 0.001 0.003 0.002 
21 Dentin sealants n.d. 0.962 n.d. n.d. 0.195 
22 Laser 0.002 < 0.001 < 0.001 < 0.001 < 0.001 
23 Potassium Citrate n.d. n.d. n.d. n.d. n.d. 
24 HEMA n.d. n.d. n.d. n.d. n.d. 
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Figure legends 
Figure 1 – PRISMA flow diagram of the study selection 
Figure 2 – Summary of methodological quality assessment of the RCT studies of the 
systematic review 
Figure 3 – Hypersensitivity reduction with potassium nitrate treatment over time. The results 
were expressed in median and minimum and maximum value. (* statistical differences 
compared to day 1 follow-up; # statistical differences compared to days 2-7 follow-up; $ 
statistical differences compared to days 8-15 follow-up; O Outlier). Different levels of 
significance: 1 symbol – p < 0.05; 2 symbols – p < 0.01; 3 symbols – p < 0.001 
 
Figure 4 – Hypersensitivity reduction with hydroxyapatite treatment over time. The results 
were expressed in median and minimum and maximum value. (* statistical differences 
compared to days 8-15 follow-up). Different levels of significance: 1 symbol – p < 0.05; 2 

















































































This article is protected by copyright. All rights reserved. 
 
 
